April 1, 2016

The Column Group Raises $535 Million Third Fund

SAN FRANCISCO – The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the final closing of TCG III, raising $535 million in an oversubscribed fund. With TCG III, the firm will continue to execute on the strategy it has deployed since inception – assembling a focused portfolio of “big idea” companies, each built from the ground up and capable of generating multiple differentiated product opportunities. To date, TCG has raised $1.1 billion. “We are grateful for the strong support for our model and significant interest from our existing and new investors,” said Peter Svennilson, Founder and Managing Partner of The Column Group. “Since 2007, TCG has been dedicated to early stage drug discovery investment as a compelling path to value creation driven by the advancement of new, highly effective human therapies. We believe that focus is critical and will continue to deploy a hands-on approach to building small cohort of high quality, science-driven companies for our third fund.”

About The Column Group
The Column Group is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas.

For more information, please visit www.thecolumngroup.com.

The Column Group Portfolio Companies
NGM Biopharmaceuticals, Constellation Pharmaceuticals, Immune Design, Igenica, Aragon Pharmaceuticals (acquired by Johnson & Johnson in 2013), Nurix, Carmot Therapeutics, Peloton Therapeutics, Seragon Pharmaceuticals (acquired by Roche in 2014), Flexus Biosciences (acquired by Bristol Myers Squibb in 2015), eFFECTOR Therapeutics, ORIC Pharmaceuticals, Neurona Therapeutics, FLX Bio, Arcus Biosciences, Gritstone Oncology, Kallyope, Ribon Therapeutics, and Surrozen.